Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis.
Pavel AB, Song T, Kim HJ, Del Duca E, Krueger JG, Dubin C, Peng X, Xu H, Zhang N, Estrada YD, Denis L, Rao N, Gupta S, Zammit DJ, Bissonnette R, Guttman-Yassky E.
Pavel AB, et al. Among authors: denis l.
J Allergy Clin Immunol. 2019 Oct;144(4):1011-1024. doi: 10.1016/j.jaci.2019.07.013. Epub 2019 Jul 26.
J Allergy Clin Immunol. 2019.
PMID: 31356921
Clinical Trial.